First Anticoagulant Oral film for Patients with Dysphagia

In reducing the risk of stroke and systemic embolism in nonvalvular atrial fibrillation (NVAF), all of the mainstream treatment options are oral tablets or injections. While most of the NVAF patients are elderly, many would have swallowing difficulty in taking pills.

To address this unmet need, TAHO is developing the first anticoagulant oral film that does not need swallowing. An easy and convenient medication for both elderly with NVAF or younger patients with pulmonary embolism (PE). Addressing an over $12 billion global novel anticoagulant market.


Click the numbers in sequence.